Electrochemical methods and devices for amending urine samples for immunosensor detection

• US 10,234,450 B2
• Filed: 03/29/2017
• Issued: 03/19/2019
• Est. Priority Date: 03/14/2013
• Status: Active Grant

• Current Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Di Tullio, Katrina, Collier, G. Bruce, Campbell, John Lewis Emerson
• Primary Examiner(s): Crawford, Erik B
• Application Number:
  US15/472,553
• Publication Number:
  US 20170199181A1
• Time in Patent Office: 720 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/58 involving urea or urease
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/5438 Electrodes
• CPC Class Codes: G01N 33/54393 Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
• CPC Class Codes: G01N 33/62 involving urea
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.

Claims

1. A method for performing an immunoassay for a target analyte in an amended urine sample, the method comprising:

providing a test device comprising;

a first region comprising reagents; and

a second region comprising a sensor comprising at least one electrode coated with a capture molecule capable of binding to the target analyte to form an immunocomplex, wherein the reagents comprise;

(i) a water soluble protein for blocking non-specific binding of immunoglobulins at the at least one electrode, (ii) a buffer, and (iii) a scavenger for reducing non-specific current generation from electroactive species at the at least one electrode;

contacting a urine sample with the reagents in the first region to amend the urine sample such that a dissolved concentration of the water soluble protein within the amended urine sample is in a range of about 0.02 to 225 mg/mL;

contacting the amended urine sample with the second region to form the immunocomplex; and

determining a concentration of the target analyte within the amended urine sample by detecting the immunocomplex using the at least one electrode.

2. The method of claim 1, wherein:

the water soluble protein is recombinant or non-recombinant human serum albumin, porcine serum albumin, castor bean albumin, salmon serum albumin, bovine serum albumin, or a mixture thereof.

3. The method of claim 1, further comprising amending the urine sample with urease to reduce a urea concentration of the urine sample below a preselected urea threshold.

4. The method of claim 1, wherein the target analyte is neutrophil gelatinase-associated lipocalin (NGAL).

5. The method of claim 1, wherein:

the buffer adjusts a pH of the urine sample to within a preselected range; and

the buffer is selected from the group consisting of;

glycine, 3-(N-morpholino) propanesulfonic acid (MOPS), tris(hydroxymethyl)aminomethane (Tris), tricine, acetate, borate, 2-(N-morpholino)ethanesulfonic acid (MES), and 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES).

6. The method of claim 1, further comprising amending the urine sample with glutamine synthetase or any other urea cycle enzyme to consume ammonium.

7. The method of claim 1, further comprising amending the urine sample with a sequestering enzyme to reduce and sequester excess phosphate below a preselected phosphate threshold.

8. The method of claim 7, wherein the sequestering enzyme is adenylate kinase.

9. A method for performing an immunoassay for a target analyte in an amended urine sample, the method comprising:

introducing an undiluted or partially diluted urine sample into a sample chamber of a cartridge through a sample entry port;

amending the urine sample with reagents such that a dissolved concentration of water soluble protein within the amended urine sample is in a range of about 0.02 to 225 mg/mL, wherein the reagents comprise;

(i) a water soluble protein for blocking non-specific binding of immunoglobulins at a sensor, (ii) a buffer, (iii) a conjugate molecule labeled with an enzyme capable of binding to the target analyte, and (iv) a scavenger for reducing non-specific current generation from electroactive species at at least electrode;

contacting the amended urine sample with a sensor on the cartridge, wherein the sensor comprises a capture molecule and the at least one electrode, the a capture molecule is capable of binding to the target analyte bound to the conjugate molecule labeled with the enzyme to form an immunocomplex, and the at least one electrode is configured to detect the immunocomplex; and

determining a concentration of the target analyte within the amended urine sample by detecting the immunocomplex using the at least one electrode.

10. The method of claim 9, wherein:

the water soluble protein is recombinant or non-recombinant human serum albumin, porcine serum albumin, castor bean albumin, salmon serum albumin, bovine serum albumin, or a mixture thereof.

11. The method of claim 9, further comprising amending the urine sample with urease to reduce a urea concentration of the urine sample below a preselected urea threshold.

12. The method of claim 9, wherein the target analyte is neutrophil gelatinase-associated lipocalin (NGAL).

13. The method of claim 9, wherein:

the buffer adjusts a pH of the urine sample to within a preselected range; and

the buffer is selected from the group consisting of;

glycine, 3-(N-morpholino) propanesulfonic acid (MOPS), tris(hydroxymethyl)aminomethane (Tris), tricine, acetate, borate, 2-(N-morpholino)ethanesulfonic acid (MES), and 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES).

14. The method of claim 9, further comprising amending the urine sample with glutamine synthetase or any other urea cycle enzyme to consume ammonium.

15. The method of claim 9, further comprising amending the urine sample with a sequestering enzyme to reduce and sequester excess phosphate below a preselected phosphate threshold.

16. The method of claim 15, wherein the sequestering enzyme is adenylate kinase.